The 2 biomarkers, SGK1 and ENPP1, and 2 chemical compounds, Stepholidine and Adenosine triphosphate, were first discovered playing a potential role in the treatment of BPH. This evidence concerns the gene ENPP1 and benign prostatic hyperplasia.